Icon Advisers Inc. Co. lessened its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 26,130 shares of the pharmaceutical company’s stock after selling 680 shares during the quarter. Icon Advisers Inc. Co.’s holdings in Vertex Pharmaceuticals were worth $5,036,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of VRTX. Kaizen Advisory LLC raised its position in shares of Vertex Pharmaceuticals by 147.3% in the 2nd quarter. Kaizen Advisory LLC now owns 601 shares of the pharmaceutical company’s stock worth $102,000 after buying an additional 358 shares during the period. Sun Life Financial INC raised its position in shares of Vertex Pharmaceuticals by 266.1% in the 2nd quarter. Sun Life Financial INC now owns 692 shares of the pharmaceutical company’s stock worth $118,000 after buying an additional 503 shares during the period. Stratos Wealth Partners LTD. purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth $123,000. Flagship Harbor Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth $125,000. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Vertex Pharmaceuticals by 3,126.1% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 742 shares of the pharmaceutical company’s stock worth $126,000 after buying an additional 719 shares during the period. 93.51% of the stock is currently owned by institutional investors.
In related news, EVP David Altshuler sold 2,125 shares of the stock in a transaction on Tuesday, August 28th. The stock was sold at an average price of $181.89, for a total value of $386,516.25. Following the completion of the sale, the executive vice president now directly owns 41,238 shares in the company, valued at approximately $7,500,779.82. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Thomas Graney sold 1,076 shares of the stock in a transaction on Monday, October 1st. The shares were sold at an average price of $193.24, for a total value of $207,926.24. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,425 shares of company stock valued at $5,095,719. 0.75% of the stock is owned by insiders.
Shares of NASDAQ VRTX opened at $175.23 on Wednesday. Vertex Pharmaceuticals Incorporated has a 12-month low of $136.50 and a 12-month high of $194.92. The firm has a market capitalization of $44.29 billion, a P/E ratio of 219.04, a P/E/G ratio of 1.72 and a beta of 1.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.71 and a quick ratio of 3.59.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, October 24th. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.07. Vertex Pharmaceuticals had a return on equity of 22.92% and a net margin of 22.87%. The firm had revenue of $784.54 million during the quarter, compared to the consensus estimate of $782.95 million. During the same period in the prior year, the firm earned $0.53 EPS. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post 2.55 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Holdings Decreased by Icon Advisers Inc. Co.” was first published by Week Herald and is the property of of Week Herald. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://weekherald.com/2018/11/07/vertex-pharmaceuticals-incorporated-vrtx-holdings-decreased-by-icon-advisers-inc-co.html.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.